Patents-Review.com
🔗 Permalink
Assignee profile:

ObsEva S.A.

City:

Plan-les-Ouates

Country:

Switzerland

Published Applications:

12

Last publication date:

2021-02-18

Patent Grants:

12

Last grant date:

2022-04-26

Top Inventors for applications by ObsEva S.A.

These are the the leading inventors for applications assigned to ObsEva S.A.:

Recent patent applications by ObsEva S.A.

ObsEva S.A. based in Plan-les-Ouates, CH has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2021-02-18 ✅ Patent 11,312,683 granted on 2022-04-26
US20210047266A1
Chemistry; metallurgy

Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists

 #2 | 2020-09-10 ✅ Patent 11,419,851 granted on 2022-08-23
US20200281892A1
Human necessities

Oral formulations of pyrrolidine derivatives

 #3 | 2020-06-11 ✅ Patent 11,759,464 granted on 2023-09-19
US20200179390A1
Human necessities

Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

 #4 | 2020-05-21 ✅ Patent 11,524,003 granted on 2022-12-13
US20200155515A1
Human necessities

Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

 #5 | 2019-01-03 ✅ Patent 10,555,934 granted on 2020-02-11
US20190000812A1
Human necessities

Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

 #6 | 2018-11-01 ✅ Patent 10,478,420 granted on 2019-11-19
US20180311211A1
Human necessities

Oral formulations of pyrrolidine derivatives

 #7 | 2018-08-02 ✅ Patent 10,604,482 granted on 2020-03-31
US20180215708A1
Chemistry; metallurgy

Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists

 #8 | 2017-11-09 ✅ Patent 10,752,583 granted on 2020-08-25
US20170320822A1
Chemistry; metallurgy

Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same

 #9 | 2017-08-24 ✅ Patent 10,047,048 granted on 2018-08-14
US20170240508A1
Chemistry; metallurgy

Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists

 #10 | 2016-01-07 ✅ Patent 9,718,772 granted on 2017-08-01
US20160002160A1
Chemistry; metallurgy

Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same

 #11 | 2015-06-18 ✅ Patent 9,962,367 granted on 2018-05-08
US20150164859A1
Human necessities

Oral formulations of pyrrolidine derivatives

 #12 | 2015-03-12 ✅ Patent 9,670,155 granted on 2017-06-06
US20150073032A1
Chemistry; metallurgy

Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists

Also check out ObsEva S.A.'s (Plan-les-Ouates, Switzerland) applicant profile with 16 patent applications submitted.

AssigneeID:

159245 ⎘